A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses

A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses

BackgroundPrevious studies have demonstrated enhanced efficacy of vaccine formulations that incorporate the chemokine macrophage inflammatory protein 3α (MIP-3α) to direct vaccine antigens to immature dendritic cells. To address the reduction in vaccine efficacy associated with a mutation in severe...

Full description

Bibliographic Details
Main Authors: James Tristan Gordy, Yinan Hui, Courtney Schill, Tianyin Wang, Fengyixin Chen, Kaitlyn Fessler, Jacob Meza, Yangchen Li, Alannah D. Taylor, Rowan E. Bates, Petros C. Karakousis, Andrew Pekosz, Jaiprasath Sachithanandham, Maggie Li, Styliani Karanika, Richard B. Markham
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
vaccine
dendritic cell
MIP-3α
intranasal (IN)
T-cell response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1292059/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1292059/full

Similar Items